A Systematic Literature Review and Bucher Indirect Comparison: Tildrakizumab versus Guselkumab
**Background:** Psoriasis is a chronic inflammatory skin condition that impacts quality of life and requires long-term treatment and effective symptom management. Interleukin-23 (IL-23) has emerged as a key player in the pathogenesis of psoriasis and tildrakizumab and guselkumab are both immunomodul...
Saved in:
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2020-07-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/jheor.2020.13671 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|